Verastem Non-GAAP EPS of -$0.54 beats by $0.07, revenue of $11.2M beats by $5.44M
Source: SeekingAlpha
2025-11-04 07:34:22 ET
More on Verastem
- Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)
- Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
- Verastem Q3 2025 Earnings Preview
- Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
Read the full article on Seeking Alpha
For further details see:
Verastem Non-GAAP EPS of -$0.54 beats by $0.07, revenue of $11.2M beats by $5.44M
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-1.9% G/L:
$5.616 Last:
118,230 Volume:
$5.61 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
